MBRX

Moleculin Biotech's stock (MBRX) has experienced significant volatility and a substantial decline over the past year, with a decrease of approximately 77.87% in the last six months. Key events include a February 2026 warrant exercise and dilution, which caused the stock to drop due to potential dilution of existing shareholders. The MIRACLE trial reached its 45-subject enrollment milestone, triggering preparations for an interim unblinding of data. Preclinical data presented at AACR 2026 showed Annamycin extended survival in metastatic pancreatic cancer models. An abstract highlighting Annamycin data was accepted for poster presentation at the 2026 ASCO Annual Meeting. Moleculin announced the issuance of a Hong Kong patent covering its method of reconstituting liposomal Annamycin. The company released CEO Corner segments highlighting Annamycin's non-cardiotoxic profile.